会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 97. 发明专利
    • Evaluation and treatment of bradykinin-mediated disorders
    • AU2018260845A1
    • 2018-11-22
    • AU2018260845
    • 2018-11-07
    • DYAX CORP
    • SEXTON DANIEL JFAUCETTE RYANKENNISTON JON ACONLEY GREGNIXON ANDREWTENHOOR CHRISTOPHERADELMAN BURTCHYUNG YUNG
    • C07K16/40
    • EVALUATION AND TREATMENT OF BRADYKININ-MEDIATED DISORDERS The present disclosure provides methods for determining a value of cleaved kininogen, intact kininogen, or both, in a sample, the method comprising contacting a sample containing intact and cleaved kininogen with a detection reagent under conditions allowing for interaction between the detection agent and the intact and cleaved kininogen, wherein the detection agent specifically binds cleaved kininogen as compared to intact kininogen, or specifically binds intact kininogen as compared to cleaved kininogen; measuring the level of cleaved kininogen and the level of intact kininogen in the sample based on their interaction with the detection reagent; and determining a value of the cleaved kininogen, the value of the intact kininogen, or both, in the sample based on the amounts of the cleaved kininogen and intact kininogen. The present disclosure also provides methods of evaluating a subject, e.g., a subject at risk for or suffering from a pKal-mediated or bradykinin-mediated disorder, based on values (e.g., percentages) of intact and/or cleaved kininogen in a sample of the subject. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment. Such methods can involve the use of a detection agent that preferentially binds cleaved kininogen or intact kininogen.